The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD
- PMID: 14989709
- DOI: 10.1111/j.0001-2815.2004.00182.x
The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD
Abstract
HLA allele mismatches will provoke T-cell alloreactivity after allogeneic stem cell transplantation. As donors and recipients are usually HLA matched, the public HLA epitopes that are recognized by natural killer (NK) cells (NK epitopes) are rarely mismatched, and therefore there is rarely potential for NK alloreactivity arising from the absence of ligands for inhibitory killer immunoglobulin-like receptors (KIR). Transplants using related donors sharing only one haplotype (haploidentical donors) represent a setting in which NK epitopes are often mismatched, thus resulting in the potential for NK alloreactivity. We have analyzed engraftment, acute graft vs host disease (GVHD), leukemia relapse, and survival in 62 haploidentical transplants in relationship with potential NK alloreactivity, inhibitory, and activating KIR genes of class I HLA NK epitopes. Potential NK alloreactivity in the rejection direction was not associated with any outcome variable. Potential NK alloreactivity in the GVHD direction was associated with an increased incidence of severe GVHD and poorer patient survival but not with non-engraftment nor leukemia relapse. A higher number of activating KIR receptors in the genome of the donor was associated with a higher prevalence of GVHD. These results suggest that lack of extensive T-cell depletion in haploidentical transplantation is associated with high GVHD rates and diminishes the benefits of NK-cell alloreactivity.
Similar articles
-
Natural killer cell HLA-C epitopes and killer cell immunoglobulin-like receptors both influence outcome of mismatched unrelated donor bone marrow transplants.Tissue Antigens. 2005 Jun;65(6):519-28. doi: 10.1111/j.1399-0039.2005.00396.x. Tissue Antigens. 2005. PMID: 15896199
-
The impact of donor natural killer cell alloreactivity on allogeneic hematopoietic transplantation.Transpl Immunol. 2005 Aug;14(3-4):203-6. doi: 10.1016/j.trim.2005.03.008. Transpl Immunol. 2005. PMID: 15982564 Review.
-
Low number of donor activating killer immunoglobulin-like receptors (KIR) genes but not KIR-ligand mismatch prevents relapse and improves disease-free survival in leukemia patients after in vivo T-cell depleted unrelated stem cell transplantation.Transplantation. 2006 Oct 27;82(8):1024-30. doi: 10.1097/01.tp.0000235859.24513.43. Transplantation. 2006. PMID: 17060849
-
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants.Science. 2002 Mar 15;295(5562):2097-100. doi: 10.1126/science.1068440. Science. 2002. PMID: 11896281
-
Natural killer cell recognition of missing self and haploidentical hematopoietic transplantation.Semin Cancer Biol. 2006 Oct;16(5):404-11. doi: 10.1016/j.semcancer.2006.07.007. Epub 2006 Jul 8. Semin Cancer Biol. 2006. PMID: 16916611 Review.
Cited by
-
Killer Cell Immunoglobulin-Like Receptor-Ligand Matching and Outcomes after Unrelated Cord Blood Transplantation in Acute Myeloid Leukemia.Biol Blood Marrow Transplant. 2016 Jul;22(7):1284-1289. doi: 10.1016/j.bbmt.2016.04.007. Epub 2016 Apr 16. Biol Blood Marrow Transplant. 2016. PMID: 27090957 Free PMC article.
-
What is the role for donor natural killer cells after nonmyeloablative conditioning?Biol Blood Marrow Transplant. 2009 May;15(5):580-8. doi: 10.1016/j.bbmt.2009.01.018. Biol Blood Marrow Transplant. 2009. PMID: 19361750 Free PMC article.
-
Natural Killer Cells: Angels and Devils for Immunotherapy.Int J Mol Sci. 2017 Aug 29;18(9):1868. doi: 10.3390/ijms18091868. Int J Mol Sci. 2017. PMID: 28850071 Free PMC article. Review.
-
Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation.Biol Blood Marrow Transplant. 2010 Apr;16(4):533-42. doi: 10.1016/j.bbmt.2009.11.022. Epub 2009 Dec 2. Biol Blood Marrow Transplant. 2010. PMID: 19961944 Free PMC article. Clinical Trial.
-
Haploidentical Transplantation in Children with Acute Leukemia: The Unresolved Issues.Adv Hematol. 2016;2016:3467672. doi: 10.1155/2016/3467672. Epub 2016 Mar 24. Adv Hematol. 2016. PMID: 27110243 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials